• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Diabetes Prevention Program Outcomes Study Reports 22-year Results

Slideshow

New data from the Diabetes Prevention Outcomes Study shows persistent reduction of type 2 diabetes development over 22-year average follow-up.

Long-term follow-up of participants enrolled in the Diabetes Prevention Program Outcomes Study (DPPOS) demonstrates a significant and persistent reduction in risk for type 2 diabetes. The latest DPPOS results were presented at the American Diabetes Association 80th Virtual Scientific Sessions. The DPP/DPPOS is the largest and longest running diabetes prevention study that continues to actively follow participants.

In the short slide show below, find highlights from the symposium, “New Data on Clinical Outcomes from the Diabetes Prevention Program Outcomes Study (DPPOS).”

Related Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Related Content
Untreated, New-Onset Hypertension Tied to Higher Risk of Uterine Fibroids in Women / Image credit: ©AGPhotography/AdobeStock

Untreated, New-Onset Hypertension Tied to Higher Risk of Uterine Fibroids in Women

April 19th 2024
Article

Women with new-onset HTN faced a 45% greater risk of newly self-reported fibroids and those with untreated HTN had a 19% greater risk, according to a new study.

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

August 30th 2023
Podcast

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

Elevated Lp(a) Level Increased ASCVD Risk Regardless of Age, Sex, Race/Ethnicity in Pooled Primary Prevention Cohort / image credit ASCVD: ©Rasi/stock.adobe.com

Elevated Lp(a) Level Increased ASCVD Risk Regardless of Age, Sex, Race/Ethnicity in Pooled Primary Prevention Cohort

April 16th 2024
Article

Elevated lipoprotein(a) was independently associated with increased ASCVD risk across primary prevention subgroups including among those with LDL-C of 70 mg/dL.

Obesity & Type 2 Diabetes: An Expert Discussion

Obesity & Type 2 Diabetes: An Expert Discussion

June 30th 2023
Podcast

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

Individuals with CVD Consume More Daily Sodium than Recommended, According to New Data / Image credit: ©Vasiliy/AdobeStock

Individuals with CVD Consume More Daily Sodium than Recommended, According to New Data

April 9th 2024
Article

ACC.24: Adults with a history of CVD consumed more than double the recommended daily sodium amount, reported researchers.

Semaglutide 2.4 mg Improves Functional Status, Body Weight in Adults with HFpEF, Obesity, T2D / image Mikhail Kosiborod, MD St Luke's Mid America Heart institute

Semaglutide 2.4 mg Improves Functional Status, Body Weight in Adults with HFpEF, Obesity, T2D

April 8th 2024
Article

ACC.24: Results of STEP HFpEF DM showed significant improvement in quality of life measures among adults with obesity-related HFpEF and type 2 diabetes.

© 2024 MJH Life Sciences

All rights reserved.